Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.

ABSTRACT: Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis.¹ Surveillance is performed using semiannual abdominal ultrasound with or without α-fetoprotein (AFP); however, this strategy misses more than one-third of HCC at an early stage.² These data highlight a need for novel surveillance strategies with higher accuracy for early HCC detection. GALAD and Doylestown Plus are novel biomarker panels that combine multiple biomarkers with patient demographic and clinical characteristics; both demonstrated promising accuracy in phase II case-control studies;^3,4 however, case-control studies can overestimate biomarker performance, highlighting a need for phase III coho

SUBMITTER: Singal AG 

PROVIDER: S-EPMC8526617 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature